MedTrace Logo

The Effects of Inositol on Glucose Metabolism in Patients With Metabolic Syndrome at Risk of Cardiac Fibrosis

NCT05689710 · Status: SUSPENDED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-12-30

No results posted yet for this study

Summary

The study aims to evaluate the effects of an oral supplementation based on inositols and alpha-lactalbumin on principals metabolic parameters in patients with metabolic syndrome at risk of cardiac fibrosis

Conditions

  • Metabolic Syndrome
  • Cardiac Fibrosis

Interventions

DIETARY_SUPPLEMENT

Inositol and alpha-lactalbumin

The administration of an oral formulation based on inositol and alpha-lactalbumin (two sachets/day for 180 days)

Sponsors & Collaborators

  • Lo.Li.Pharma s.r.l

    lead INDUSTRY

Principal Investigators

  • Davide Grassi, MD · UOC Medicina Interna e Nefrologia P.O. AQ

  • Claudio Ferri, MD · UOC Medicina Interna e Nefrologia P.O. AQ

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-23
Primary Completion
2026-01-31
Completion
2026-01-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05689710 on ClinicalTrials.gov